We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DxGen Corp.

DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculo... read more Featured Products: More products

Download Mobile App





DxGen Launches '2 Minutes' COVID-19 Antibody Testing System

By LabMedica International staff writers
Posted on 19 May 2020
A newly-launched '2 minutes' detection system for COVID-19 IgM / IgG antibodies offers reliable testing with several attractive features for medical professionals and has also received CE Mark.

The newly-developed Epithod 616 analyzer and COVID-19 IgM/IgG test kit from DxGen Corp. More...
(South Korea) is the fastest system that not only provides positive (+, ++, +++) or negative (-) results, but also shows the results through a relative numerical value in COI (Cut-Off Index), thus enabling the user to diagnose the levels of IgM and IgG antibodies present and manage their quantitative results more specifically. The Epithod 616 diagnostic system ensures better accuracy and improved sensitivity in analyzing results and eliminates the risk of undesirable misreading which frequently occurs in conventional ‘lateral-flow’ immunoassay tests where the user determines the test results through their own naked eye.

Owing to its unique multi-chromatic reflectometry analyzer and flow-through immunoassay platform, the system can provide test results within two minutes, or more than 100 test results per hour, which significantly improves the total test capacity as compared to the conventional ‘Lateral-flow’ test kit that usually takes at least 10 minutes for each test. Additionally, the Epithod 616 is equipped with user-friendly functions, such as a ‘check-up list’ that enables the user to input patient information in detail, including fever, cough and the number of days since the onset of symptoms.

“It is very important to comprehensively monitor underlying diseases such as diabetes, myocardial infarction and pneumonia together with the COVID-19 disease in order to care the infected patients and to restrain the spread of the outbreak," said Jinwoo Lee, Ph.D., chief executive officer, DxGen Corporation. "Epithod 616 drew great attention from many potential customers who have interest in integrative diagnostics of COVID-19 with HbA1c, Glycated Albumin, CRP, hs-CRP, D-dimer and more. This is very important point to make decisions about the treatment efficacy and convalescence patients."



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.